Atea Pharmaceuticals, Inc..
AVIR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Atea Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies to address unmet medical needs for patients with severe viral diseases. The company's primary focus is on developing oral direct-acting antiviral agents for the treatment of se...Show More
Better Health for All
10
Atea Pharmaceuticals' core business is entirely focused on developing oral direct-acting antiviral agents for severe viral diseases, including Hepatitis C Virus (HCV) and COVID-19, aiming to address unmet medical needs.
1
Its entire business is devoted to health improvement. The company has no revenue from products with established negative health outcomes.
2
In Phase 1 and 2 studies for its HCV regimen, there were no drug-related serious adverse events or treatment discontinuations, and treatment-emergent adverse events were mostly mild to moderate, reported in 43% of patients.
3
Research and development expenses were $144.1 million for FY 2024 and $29.6 million for Q1 2025.
4
The company successfully engaged with the FDA in an End-of-Phase 2 meeting in January 2025 for its HCV program.
5
Fair Money & Economic Opportunity
0
Atea Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for viral diseases. The company's core business does not involve offering lending, deposit services, or any other financial products or services to consumers. Therefore, all Key Performance Indicators related to 'Fair Money & Economic Opportunity' are not applicable to its operations.
Fair Pay & Worker Respect
0
Atea Pharmaceuticals reduced its workforce by approximately 25% in Q1 2025.
1
The company's average annual salary is $126,270, with listed roles ranging from a Senior Manager, Clinical Trial at $128,832 to a General Counsel at $445,405.
2
Employee benefits include Social Security, 401(K), Disability, Healthcare, Pension, and Time Off.
3
The cost of living in Boston, where the company is located, is 53.2% higher than the US average.
4
No specific data is available regarding living wage coverage, CEO to median pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, voluntary turnover, labor law violations, insecure contract share, or the percentage of the workforce covered by health insurance.
5
Fair Trade & Ethical Sourcing
0
No evidence available to assess Atea Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-50
Atea Pharmaceuticals has a whistleblower hotline and policy in place, but there is no evidence regarding independent investigation processes, training, or uptake.
1
The company also has a code of conduct and ethics policy, but details on its specific anti-corruption guidance, enforcement, or training are not provided.
2
Kind to Animals
-60
Atea Pharmaceuticals conducts animal testing, including nonclinical safety assessments and toxicology studies of bemnifosbuvir (AT-527) in rats, rabbits, and monkeys.
1
These studies included fertility, reproduction, embryofetal and postnatal development, and repeat dose oral toxicity for up to 13 weeks.
2
While the company utilized in vitro genetic toxicity assays, these appear to be for early-stage screens, with extensive animal testing still employed for complex endpoints.
3
The company has no publicly disclosed policy for reducing animal testing or transparent reduction targets.
4
It is noted to have 'Significant Involvement' in animal testing, but specific annual animal usage numbers are not disclosed, making it impossible to determine a precise volume.
5
No War, No Weapons
0
No evidence available to assess Atea Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles, which primarily focus on Atea Pharmaceuticals' financial results and general ESG ratings, do not contain specific quantitative data points for any of the 'Planet-Friendly Business' KPIs. While the company has received various ESG ratings and certifications, such as an EcoVadis Platinum rating, a CDP Climate Change 'A' rating, and an MSCI ESG 'A' rating, these are high-level assessments of overall performance and disclosure, not granular data required by the rubric for metrics like greenhouse gas emissions, renewable energy use, water consumption, or waste diversion.
1
The articles explicitly state that specific data on these key environmental metrics is not provided.
2
Furthermore, while a workforce reduction of approximately 25% was announced for Q1 2025, no information is provided regarding support programs for affected workers, which would be relevant to 'just_transition_programs'.
3
Respect for Cultures & Communities
0
The provided articles do not contain specific, concrete data points for Atea Pharmaceuticals (AVIR.US) regarding its respect for cultures and communities. There is no evidence found for formal partnerships with indigenous or local community groups, percentage of revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC participation rates, community governance inclusion, cultural preservation investment, local procurement share, indigenous supplier count, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
1
General discussions about traditional knowledge in drug development or federal guidelines for Indigenous consultation are not company-specific evidence.
Safe & Smart Tech
0
The company states it has not experienced any material cybersecurity incidents affecting its operations, business strategy, results, or financial condition.
1
No specific regulatory actions, violations, fines, or compliance issues are mentioned.
2
Atea Pharmaceuticals has a cybersecurity risk management program, guided by the NIST CSF, which includes risk assessments, a security team, external service providers, employee training, an incident response plan, and a third-party risk management process.
3
The Board and Audit Committee oversee cybersecurity risks, receiving periodic reports from management, and the IT team is led by a VP with over 25 years of experience.
4
Zero Waste & Sustainable Products
0
The provided articles discuss sustainability initiatives, ESG ratings, and IT equipment recovery for reuse and recycling, all pertaining to 'Atea,' an IT company. The company to be assessed is AVIR.US (Atea Pharmaceuticals, Inc.), a biopharmaceutical company.
1
The articles explicitly state that no specific data is provided regarding AVIR.US or its performance related to 'Zero Waste & Sustainable Products.'
2
Therefore, no KPIs can be scored for Atea Pharmaceuticals, Inc. based on the evidence provided.